CNTN
Canton Strategic (CNTN)
NASDAQ
$2.11+$0.09 (+4.55%)
Price as of Aug 14, 2026 7:55 PM EDT
  • $155.8M
    Market Cap
  • N/A
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: N/A
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Canton Strategic Holdings, Inc. Expected to Be Included in Russell 3000® and Russell 2000®

Canton Strategic Holdings, Inc. (NASDAQ: CNTN) announced it is expected to be included in the Russell 3000® Index and Russell 2000® Index following the semi-annual reconstitution effective June 26, 2026. The company is the first publicly traded firm to leverage Canton Coin to support the Canton Network's digitization of traditional financial markets.

06/18/2026, 8:15 AM • Benzinga

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.

09/03/2025, 7:30 AM • The Motley Fool

Stock Market Today: Dow, S&P 500 Futures Tumble As Jobless Claims Increase— Walmart, Intuit, Ross Stores Earnings In Focus (UPDATED)

U.S. stock futures were slightly lower as the Jackson Hole Economic Symposium begins, with focus on Federal Reserve Chair Jerome Powell's upcoming speech and key corporate earnings reports from Walmart, Intuit, and Ross Stores.

08/21/2025, 8:38 AM • Benzinga

Peers

Statistics

More
Day Range
$1.90
$2.09
$2.02
1-Year Range
$1.85
$5.14
$2.02
Latest Close$2.02
Change
+$0.05 (+2.48%)
Volume747,915
Market Cap$155.8M
Shares Outstanding77.1M
P/E (TTM)-15.37
Diluted EPS (TTM)-$0.13
Enterprise Value$118.5M

Information as of 08/14/2026

Company Profile

CANTON STRATEGIC HOLDINGS INC
CANTON STRATEGIC HOLDINGS INC
https://www.cantonstrategic.com
$155.8M
Market Cap
-$18.0M
Net Income
Sector: Healthcare
Industry: Biotechnology
34 Shrewsbury Avenue, Red Bank, NJ, United States, 07701
732 889 3111

Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States. It operates in two segments, Digital Asset Treasury and Clinical Stage Bio-technology. The company is involved in the operation of Canton Coin-centric digital asset treasury strategies, including validator operations and network participation; application support and strategic investments; collaboration and ecosystem advancement; capital raising and treasury expansion; token management - locking, lending, and options; Canton Foundation; and governance and risk management. It also researches and develops GV104, a buccal film formulation of nalmefene for the treatment of respiratory depression and prophylactic protection against synthetic opioid exposure in military and first responders; and GV023, an oral anti-tumor necrosis factor-alpha monoclonal antibody that addresses critical limitation of IV gold standard for the treatment of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was incorporated in 2017 and is headquartered in Red Bank, New Jersey.

Key Executives

  • Mark Toomey
  • Jacob Asbury
  • Mark Wendland
  • Angela Dominy Radkowski

Current Ownership Distribution

  • Other56.2M (72.90%)
  • Institutions12.2M (15.88%)
  • Mutual Funds8.5M (11.01%)
  • Insiders169,526 (0.22%)